Caspofungin
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | CANCIDAS | — | 2002-09-20 – 2009-06-26 | fda.gov ↗ |
| Approved | EU (EMA) | Cancidas (previously Caspofungin MSD) | — | 2001-10-23 | europa.eu ↗ |
| Approved | US (FDA) | CANCIDAS | — | 2001-01-26 | fda.gov ↗ |
Trials 49 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 15 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02856178 Background | Apr 2017 | acute myeloid leukemia, invasive aspergillosis | F2G Ltd | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06194201 Comparator | Apr 2024 → Jun 2026 | candidiasis | Fujian Shengdi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02734862 Comparator | Jul 2016 → Jun 2019 | candidemia | Cidara Therapeutics Inc. | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT05421858 Comparator | Dec 2024 → Jan 2028 expected | candidemia | Basilea Pharmaceutica | Recruiting | No outcome recorded |
| Phase 3 | NCT05178862 Background | Aug 2022 → Nov 2025 | candidemia | Scynexis, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03667690 Comparator | Oct 2018 → Oct 2021 | candidemia | Cidara Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01058174 Comparator | Dec 2009 → May 2012 | fungal infectious disease | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00413218 Comparator | Mar 2007 → Mar 2015 | candidemia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00105144 Comparator | Sep 2004 → Apr 2006 | candidemia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00665639 Comparator | Jun → Dec 2004 | oral candidiasis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT04728971 Comparator | Oct 2022 → Oct 2025 | — | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT02895529 Comparator | Nov 2016 → May 2018 | hematopoietic and lymphoid cell neoplasm | Xian-Janssen Pharmaceutical Ltd. | Terminated | No outcome recorded |
| Phase 4 | NCT00839540 Comparator | Dec 2008 → May 2010 | candidemia | Gary E. Stein, Pharm.D. | Completed | No outcome recorded |
| Phase 4 | NCT00520234 Comparator | Aug 2007 → Mar 2010 | candidiasis, invasive | Mycoses Study Group | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00982540 Comparator | Feb 2010 → Nov 2013 | fusariosis, invasive aspergillosis | Federal University of Rio de Janeiro | Terminated | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 66 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Caspofungin | “Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants.” PMID 19841031 ↗ Oct 200954“The patients included in this protocol require routine treatment with caspofungin or micafungin.” NCT02805049 ↗ “Caspofungin: 70 mg on the first day of therapy, followed by 50 mg q.d.” NCT01501708 ↗ “Caspofungin” NCT05178862 ↗ |
| Known as | Cancidas | “Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit” NCT02510053 ↗2“Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection” NCT00806351 ↗ “Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection” NCT00805740 ↗ |
| Known as | Cancidas (previously caspofungin msd) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | Caspofungin (as acetate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | Caspofungin accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | caspofungin acetate | “Giving caspofungin acetate may be effective in preventing or controlling fever and neutropenia caused by chemotherapy or bone marrow transplantation.” NCT00020527 ↗13“Subjects receive Caspofungin acetate 50mg/day IV for 28 days.” NCT00095316 ↗ “MK0991, caspofungin acetate/Duration of Treatment: variable” NCT00083343 ↗ “MK0991, caspofungin acetate / Duration of Treatment:” NCT00548080 ↗ “caspofungin acetate (MK0991)” NCT00717860 ↗ “MK0991, caspofungin acetate” NCT00076869 ↗ “Drug: Caspofungin acetate” NCT01045798 ↗ |
| Known as | Caspofungin Acetate for Injection | “Drug: Caspofungin Acetate for Injection” NCT06194201 ↗ |
| Known as | Caspofungin diacetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | Caspofungina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | Caspofungine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | L-743,872 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005920 ↗ |
| Known as | MK0991 | “MK0991, caspofungin acetate/Duration of Treatment: variable” NCT00083343 ↗3“MK0991, caspofungin acetate / Duration of Treatment:” NCT00548080 ↗ “caspofungin acetate (MK0991)” NCT00717860 ↗ |
| Action | Inhibit | “glucan synthase inhibitor” NCT00095316 ↗ |
| Modality | Other / unclassified | “echinocandin” NCT00839540 ↗ |
| Route | Intravenous | “administered intravenously by a peripheral line” NCT00005920 ↗ |